MedTrace Logo

Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.

NCT00335725 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2015-03-27

Study results available
· View outcomes & findings →

Summary

Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Serono) when administered in patients undergoing ICSI

Conditions

Interventions

DRUG

Follicle Stimulating Hormone

subcutaneous injection of FSH. Starting dose: 225 IU.

DRUG

Follicle Stimulating Hormone

subcutaneous injection of FSH. Starting dose: 225 IU.

Sponsors & Collaborators

  • IBSA Institut Biochimique SA

    lead INDUSTRY

Principal Investigators

  • J G Grudzinskas, Prof · The Bridge Centre One St Thomas Street London Bridge London SE1 9RY, UK2.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • France
  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00335725 on ClinicalTrials.gov